$BSX — Medical devices for cardiovascular, neuromodulation, and endoscopy.

$BSX — Medical devices for cardiovascular, neuromodulation, and endoscopy. 🎯 Q1 FY26 | Rev $5B | EPS $0.80 vs $0.79 🟢 | Margin 21.2% 💡 Consensus expects steady mid-single-digit revenue growth and margin expansion from BSX's medtech portfolio. The 1.6% EPS beat is modest and already priced in. The market may be underestimating the impact of recent restructuring charges and a sharp drop in operating cash flow (down 36% YoY), which could signal working capital strain or one-time... 🏢 Business Quality: 8/10 | Valuation: fair 📉 Reward/Risk: Upside 8% to $51.50 (15x FY26 EPS) vs downside 12% to $42 (12.5x FY26 EPS) if cash flow disappoints. Ratio 0.67:1, unfavorable for active long. 🔮 Catalyst: Q2 2026 earnings (late July): watch for revenue acceleration to >5% organic growth and operating cash flow recovery above $500M. Failure signal: operating cash flow remains below $400M or guidance cut. Also in play: $BXP $KRC $SLG $DEI $FRT

🎯 Q1 FY26 | Rev $5B | EPS $0.80 vs $0.79 🟢 | Margin 21.2%